PMID- 33400835
OWN - NLM
STAT- MEDLINE
DCOM- 20211203
LR  - 20211214
IS  - 1549-4918 (Electronic)
IS  - 1066-5099 (Linking)
VI  - 39
IP  - 4
DP  - 2021 Apr
TI  - Robust parameter design of human induced pluripotent stem cell differentiation 
      protocols defines lineage-specific induction of anterior-posterior gut tube 
      endodermal cells.
PG  - 429-442
LID - 10.1002/stem.3326 [doi]
AB  - Tissues and cells derived from pluripotent stem cells (PSC) are likely to become 
      widely used in disease modeling, drug screening, and regenerative medicine. For 
      these applications, the in vitro PSC differentiation process must be elaborately 
      investigated and controlled to reliably obtain the desired end products. However, 
      because traditional experimental methods, such as one factor at a time or 
      brute-force approaches, are impractical for detailed screening of complex PSC 
      cultivation conditions, more strategic and effective screening based on 
      statistical design of experiments (DOE) ought to be indispensable. Among various 
      DOE approaches, we regard robust parameter design (RPD) as particularly suited 
      for differentiation protocol optimization due to its suitability for 
      multifactorial screening. We confirmed the adaptability of RPD for investigating 
      human induced PSC lineage specification toward anterior-posterior gut tube 
      endodermal cells and clarified both the contribution of each cell signaling 
      pathway and the effect of cell signaling condition alteration on marker RNA 
      expression levels, while increasing the efficiency of the screening in 243-fold 
      (18 vs 4374) compared with that of a brute-force approach. Specific induction of 
      anterior foregut, hepatic, pancreatic, or mid-hindgut cells was achieved using 
      seven iPSC strains with the optimal culture protocols established on the basis of 
      RPD analysis. RPD has the potential to enable efficient construction and 
      optimization of PSC differentiation protocols, and its use is recommended from 
      fundamental research to mass production of PSC-derived products.
CI  - (c)AlphaMed Press 2021.
FAU - Yasui, Ryota
AU  - Yasui R
AUID- ORCID: 0000-0002-5088-7696
AD  - Department of Regenerative Medicine, Yokohama City University Graduate School of 
      Medicine, Yokohama, Kanagawa, Japan.
AD  - Fundamental Research Laboratory, Eiken Chemical Co., Ltd., Nogi, Tochigi, Japan.
FAU - Sekine, Keisuke
AU  - Sekine K
AUID- ORCID: 0000-0001-5133-0876
AD  - Department of Regenerative Medicine, Yokohama City University Graduate School of 
      Medicine, Yokohama, Kanagawa, Japan.
AD  - Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative 
      Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 
      Japan.
AD  - Laboratory of Cancer Cell Systems, National Cancer Center Research Institute, 
      Tokyo, Japan.
FAU - Yamaguchi, Kiyoshi
AU  - Yamaguchi K
AD  - Division of Clinical Genome Research, Advanced Clinical Research Center, The 
      Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
FAU - Furukawa, Yoichi
AU  - Furukawa Y
AD  - Division of Clinical Genome Research, Advanced Clinical Research Center, The 
      Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
FAU - Taniguchi, Hideki
AU  - Taniguchi H
AD  - Department of Regenerative Medicine, Yokohama City University Graduate School of 
      Medicine, Yokohama, Kanagawa, Japan.
AD  - Division of Regenerative Medicine, Center for Stem Cell Biology and Regenerative 
      Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, 
      Japan.
AD  - Advanced Medical Research Center, Yokohama City University Graduate School of 
      Medicine, Yokohama, Kanagawa, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210115
PL  - England
TA  - Stem Cells
JT  - Stem cells (Dayton, Ohio)
JID - 9304532
RN  - 0 (AFP protein, human)
RN  - 0 (Biomarkers)
RN  - 0 (CDX2 Transcription Factor)
RN  - 0 (CDX2 protein, human)
RN  - 0 (Homeodomain Proteins)
RN  - 0 (Octamer Transcription Factor-3)
RN  - 0 (POU5F1 protein, human)
RN  - 0 (Trans-Activators)
RN  - 0 (alpha-Fetoproteins)
RN  - 0 (pancreatic and duodenal homeobox 1 protein)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 107-92-6 (Butyric Acid)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Biomarkers/metabolism
MH  - Butyric Acid/pharmacology
MH  - CDX2 Transcription Factor/genetics/metabolism
MH  - *Cell Culture Techniques
MH  - Cell Differentiation/drug effects
MH  - Cell Line
MH  - Cell Lineage/drug effects
MH  - Endoderm/*cytology/drug effects/metabolism
MH  - Factor Analysis, Statistical
MH  - Fibroblast Growth Factor 2/pharmacology
MH  - Gene Expression
MH  - Homeodomain Proteins/genetics/metabolism
MH  - Humans
MH  - Induced Pluripotent Stem Cells/*cytology/drug effects/metabolism
MH  - Intestines/*cytology/drug effects/metabolism
MH  - Liver/*cytology/drug effects/metabolism
MH  - Octamer Transcription Factor-3/genetics/metabolism
MH  - Pancreas/*cytology/drug effects/metabolism
MH  - *Research Design
MH  - Signal Transduction
MH  - Trans-Activators/genetics/metabolism
MH  - Tretinoin/pharmacology
MH  - alpha-Fetoproteins/genetics/metabolism
OTO - NOTNLM
OT  - anterior-posterior patterning
OT  - cell differentiation
OT  - design of experiments (DOE)
OT  - endoderm
OT  - induced pluripotent stem cells
OT  - pluripotent stem cells
EDAT- 2021/01/06 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/01/05 17:12
PHST- 2020/06/08 00:00 [received]
PHST- 2020/12/07 00:00 [accepted]
PHST- 2021/01/06 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/01/05 17:12 [entrez]
AID - 10.1002/stem.3326 [doi]
PST - ppublish
SO  - Stem Cells. 2021 Apr;39(4):429-442. doi: 10.1002/stem.3326. Epub 2021 Jan 15.